Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and...
Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )
30 Jun 2022
War in Ukraine: Global cancer aid to support refugees
Dr Horia Vulpe , Dr Ruslan Baltaga
War in Ukraine: Global cancer aid to support refugees ( Dr Horia Vulpe , Dr Ruslan Baltaga )
21 Jun 2022
War in Ukraine: The International Brain Tumour Alliance's response to aiding ref...
Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance
War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis ( Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance )
21 Jun 2022
R-CODOX-M/R-IVAC versus dose-adjusted-EPOCH-R in patients with newly diagnosed h...
Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands
R-CODOX-M/R-IVAC versus dose-adjusted-EPOCH-R in patients with newly diagnosed high-risk lymphoma ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )
14 Jun 2022
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDM...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
Glofitamab induces durable complete remissions in patients with relapsed large B...
Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia
Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma ( Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia )
13 Jun 2022
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy i...
Prof Barbara Eichhorst - University of Cologne, Cologne, Germany
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )
13 Jun 2022
Quizartinib advances overall survival in acute myeloid leukaemia patients
Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA
Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )
13 Jun 2022
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for ...
Dr Elias K. Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients ( Dr Elias K. Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodg...
Dr Paul Bröckelmann - University of Cologne, Cologne, Germany
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )
13 Jun 2022
Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )
10 Jun 2022